CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Focusing on ‘Overwhelming Interest’ for GLP-1 Applications of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that it will focus on glucagon-like peptide 1 (“GLP-1”) applications of its patented DehydraTECH(TM) technology for diabetes and weight loss for the 2024 calendar year. “This comes hot on the heels of a successful, active year of R&D in 2023, a year that saw significant strides in developing its patented DehydraTECH technology including its new foray into GLP-1 drugs… This laid the groundwork for Lexaria to explore a new class of molecules it had never worked on before, ultimately quietly launching its top-priority and unpublicized early-stage work program – GLP-1 – for weight loss and diabetes control. In the words of Chris Bunka, Lexaria’s CEO, this was a ‘high-risk program,’ mainly because this class of drugs is considered ‘large molecules,’ yet all of Lexaria’s previous investigations were concentrated on ‘small molecules.’ However, by the end of November and early January 2024, the company reported positive interim and final human pilot study results using a single semaglutide dose of a Rybelsus(R) tablet to a matching dose from Rybelsus that had been compound formulated in capsule form using DehydraTECH processing technology enhancements,” a recent article reads. “Our R&D plans for 2024 are very tightly focused and will be concentrated mainly on GLP-1 investigations,” said Lexaria CEO Chris Bunka. “Given the overwhelming interest in the GLP-1 sector, this will be a main focus.”

To view the full article, visit https://cnw.fm/1Xevi

About Lexaria Bioscience Corp.

DehydraTECH(TM) is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX